Tiagabine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00906 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | visual epilepsy | KG + DL |
| 2 | restless legs syndrome | KG + DL |
| 3 | startle epilepsy | KG + DL |
| 4 | thinking seizures | KG + DL |
| 5 | audiogenic seizures | KG + DL |
| 6 | eating seizures | KG + DL |
| 7 | orgasm-induced seizures | KG + DL |
| 8 | micturation-induced seizures | KG + DL |
| 9 | status epilepticus | KG + DL |
| 10 | adolescent/adult onset autosomal dominant epilepsy with auditory features | KG + DL |
| 11 | reading seizures | KG + DL |
| 12 | epilepsy with generalized tonic-clonic seizures | KG + DL |
| 13 | beta-ketothiolase deficiency | KG + DL |
| 14 | trigeminal nerve neoplasm | KG + DL |
| 15 | 14q12 microdeletion syndrome | KG + DL |
| 16 | Rett syndrome, congenital variant | KG + DL |
| 17 | guanidinoacetate methyltransferase deficiency | KG + DL |
| 18 | partial motor epilepsy | KG + DL |
| 19 | trigeminal neuralgia | KG + DL |
| 20 | epilepsy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.